GSK revealed ideas for a large new UK-based headquarters and global campus for the new Consumer Healthcare company, after the split planned in 2022, as well as its long-term strategy for GSK’s future headquarters.
The announcement is part of GSK’s ongoing preparations to split into two leading UK-based companies next year involving new GSK a global pharmaceuticals and vaccines company with an R&D focus on immune system science, human genetics, and advanced technologies, as well as a world-leading Consumer Healthcare company with annual sales of more than £10 billion, including nine global power brands that hold category leadership positions.The newly UK-listed Consumer Healthcare company intends to build new global campus and innovation centre in Weybridge, UK.
New Consumer Healthcare company headquarters to be based in Weybridge, UK
According to the project the new global Consumer Healthcare company campus will be established in Weybridge, UK, comprising the worldwide headquarters. Moreover, it will include an innovation center with a Consumer Healthcare Shopper Science lab, R&D labs and the company’s global support function teams employing around 1400 highly skilled members.
Subject to consultation and planning clearances, the new Consumer Healthcare company will open its new headquarters by the end of 2024.
Because the company’s true separation is planned in 2022, and the new facility is still being built, the Consumer Healthcare teams will transfer from GSK House in Brentford to a provisional headquarters in Weybridge, which will be distinct from the company’s current headquarters.
Brian McNamara, CEO Designate, GSK Consumer Healthcare said:
“This investment in a new cutting-edge campus in the UK will bring together our first-in-class teams as we drive towards our ambitions as the world’s leading consumer healthcare company. Today’s announcement is an important step as we prepare for separation, marking an exciting new beginning for New Consumer Healthcare.”
GSK to move to new UK headquarters after separation
GSK will relocate to a new UK headquarters after its split. GSK will define a suitable to the new company needs site based in the same area, as the company’s current headquarters, ensuring access to the UK’s world-leading science and innovation hubs. GSK intends to provide a further update on its new headquarters in mid-2022, and expects to remain at GSK House in Brentford until at least the end of 2023.
Through separation, GSK is creating a new world-leader in Consumer Healthcare. With sales of £10 billion in 2020, the business will serve more than 100 markets, driven by strong brands and innovation, with cutting-edge science and human understanding to deliver better everyday health. With an industry-leading portfolio, including nine global brands holding category leadership positions in oral health, pain relief, cold, flu and allergy, digestive health and vitamins, minerals and supplements; significant scale in the US and China; and a further 11 brands each generating more than £100 million in sales, the business is well placed to address consumer needs and drive long term growth.